1.
Jennifer R. Brown, Wael A. Harb, Brian T. Hill, Janice Gabrilove, Jeff P. Sharman, Marshall T. Schreeder, Paul M. Barr, James M. Foran, Thomas P. Miller, Jan A. Burger, Kevin R. Kelly, Daruka Mahadevan, Shuo Ma, Yan Li, Daniel W. Pierce, Evelyn Barnett, Jeffrey Marine, Monika Miranda, Ada Azaryan, Xujie Yu, Pilar Nava-Parada, Jay Mei, Thomas J. Kipps. Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica 2016;101(7):e295-e298; https://doi.org/10.3324/haematol.2015.140806.